Medical devices, healthcare technology and the business of care
510(k) clearance · K260474

Liora Monofilament Scaffold

TELA Bio, Inc. · Decision date Sep 28, 2026

MEDTECHLEDGER EXPLANATIONK260474

What did the FDA decide?

FDA recorded a substantially equivalent (SESE) decision on September 28, 2026 for K260474, the Liora Monofilament Scaffold submitted by TELA Bio, Inc. of Malvern, Pennsylvania. The device is a sterile, resorbable monofilament scaffold made of 100% poly(lactic co-glycolic acid), classified as surgical mesh under 21 CFR 878.3300, Class II, product code FTL, in the General and Plastic Surgery specialty. Clearance is not premarket approval.

The 510(k) summary compares Liora with primary predicate Polydioxanone Surgical Scaffold (K181094) and reference devices OviTex PRS Long-Term Resorbable (K243595) and TIGR Matrix (K191749). The summary states the same intended use as the predicate, with added specification for muscle flap transfer as temporary support, and identifies differences in materials of construction, thickness, areal density and pore size. The summary asserts these differences raise no different questions of safety or effectiveness; independent clinical outcome data are not provided in the source.

Regulatory pathway
510(k) premarket notification
Clinical specialty
General, Plastic Surgery
Decision date
Sep 28, 2026

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
K260474
Regulatory pathway
510(k) premarket notification
Product code
FTL
Decision code
SESE
Decision date
Sep 28, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Mesh, Surgical, Polymeric.

Product code
FTL
FDA device class
2

FDA decision timeline

  1. K260474 received

    Application receipt date recorded by FDA.

  2. K260474 · FDA decision

    SESE

Related devices and submissions

Explore the linked device profile

No additional submissions with a verified PMA or product-code relationship are linked here.

Regulatory context

A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

TELA Bio, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Malvern, PA

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records